Glory Financial reported on December 10th that Northeast Pharmaceutical Group (000597.SZ) announced that the company's controlling Shareholder, Liaoning China Fangda Group Industrial Co., Ltd. (referred to as "China Fangda Group"), and its concerted party, Jiangxi Fangda Steel Group Co., Ltd. (hereinafter referred to as "Fangda Steel/Shareholding entity"), plan to increase their shareholding in the company within six months from the date of the announcement, with a planned increase of no less than 75 million yuan and no more than 150 million yuan. The funds for this increase will come from Fangda Steel's own funds and special loans.
东北制药(000597.SZ)：控股股东一致行动人拟增持0.75亿元-1.50亿元公司股份
Northeast Pharmaceutical Group (000597.SZ): The concerted parties of the controlling Shareholder plan to increase their Shareholding by 0.075 billion yuan to -0.15 billion yuan in the company's shares.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated